Table 3.
Synergy between MEN1611 and gefitinib in NSCLC cell lines.
| Drug | RA1 | RA2 | RB1 | |
|---|---|---|---|---|
| Dm (µM) | Gef | > 10 | > 10 | > 10 |
| MEN1611 | 4.9 –7.2 | 2.5 –5.9 | 5.5 – 10.0 | |
| Gef+MEN1611 | 1.1 –1.9 | 1.9 –4.9 | 3.5 – 6.1 | |
| CI | Gef+MEN1611 | 0.1 –0.2 | 0.2 –0.4 | 0.2 – 0.4 |
Median-effect dose (Dm) of single and combination drugs and relative combination index (CI) of EGFR-TKi resistant NSCLC cell lines, calculated at 50% of fraction affected. Gefitinib, Gef.